Research graph
References from Real-world effectiveness and predictors of need for extended induction of mirikizumab therapy in ulcerative colitis. Local targets link to admitted publications; unresolved targets remain external evidence.
Ulcerative colitis
10.1016/s0140-6736(23)00966-2 · 2023 · External reference
What does disease progression look like in ulcerative colitis, and how might it Be prevented?
10.1053/j.gastro.2022.01.023 · 2022 · External reference
Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States
10.1186/s12876-023-02675-w · 2023 · External reference
The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study
2023 · External reference
Mirikizumab as induction and maintenance therapy for ulcerative colitis
10.1056/nejmoa2207940 · 2023 · External reference
Risankizumab for ulcerative colitis: two randomized clinical trials
10.1001/jama.2024.12414 · 2024 · External reference
Patients included in clinical trials of biological drugs for inflammatory bowel disease do not represent the real-world population
10.14309/ajg.0000000000003670 · 2026 · External reference
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
10.1136/gutjnl-2024-334395 · 2025 · External reference
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
10.1053/j.gastro.2006.12.038 · 2007 · External reference
Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis
10.1002/ibd.20520 · 2008 · External reference
Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study
10.1093/ecco-jcc/jjab058 · 2021 · External reference
Real-world effectiveness and safety of mirikizumab induction therapy in patients with ulcerative colitis: a multicentre retrospective observational study
10.1111/apt.70140 · 2025 · External reference
Mirikizumab in the treatment of ulcerative colitis: initial real-world data in a population from a large tertiary center
10.1007/s10620-025-08950-y · 2025 · External reference
Mirikizumab in ulcerative colitis: real-world evidence from an international two-center retrospective cohort study
10.1177/17562848251392074 · 2025 · External reference
Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan
10.5217/ir.2025.00176 · 2026 · External reference
Extended induction and prognostic indicators of response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
10.1093/ibd/izae004 · 2024 · External reference
Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms
10.1038/clpt.2011.328 · 2012 · External reference
Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: Results from phase III LUCENT studies
10.1007/s40262-023-01281-z · 2023 · External reference
Pharmacokinetic comparability and safety between original and citrate-free mirikizumab formulations for subcutaneous injections: Results from three clinical trials
10.1007/s12325-025-03158-y · 2025 · External reference
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
10.1038/s41575-023-00768-1 · 2023 · External reference
A practical approach to positioning therapies in ulcerative colitis
10.1093/jcag/gwae058 · 2025 · External reference
